GlassScriptPhysician profile
Anthony S Kim
NPI 1356311823
$2,386.26
in general payments reported to CMS, 2019-2025
31 companies · $289 in 2025
The $289 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $233 · 2020: $324 · 2021: $524 · 2022: $442 · 2023: $317 · 2024: $258 · 2025: $289.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $818 · Education: $45.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $818.09 |
| Education | $45.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $691.23 | 2020-2025 | Trelegy Ellipta, Shingrix, Arexvy |
| Astellas Pharma US INC | $261.14 | 2019-2024 | Veozah, Myrbetriq |
| Nevro Corp. | $174.89 | 2021 | |
| Abbvie INC. | $152.96 | 2021-2025 | |
| Novo Nordisk INC | $145.87 | 2020-2025 | Rybelsus, Ozempic, Wegovy |
| Janssen Pharmaceuticals, INC | $108.83 | 2019-2022 | |
| Lilly USA, LLC | $83.18 | 2023-2025 | Jardiance, Emgality |
| Inspire Medical Systems, INC. | $76.43 | 2025 | Inspire |
| Ardelyx, INC. | $74.91 | 2023 | Ibsrela |
| Takeda Pharmaceuticals U.S.A., INC. | $71.70 | 2020-2022 | |
| Dexcom, INC. | $58.74 | 2022-2023 | Dexcom G6 Transmitter |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $49.10 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $41.95 | 2019-2025 | Jardiance |
| Pfizer INC. | $39.98 | 2019-2021 | |
| Merck Sharp & Dohme LLC | $39.15 | 2019-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sunovion Pharmaceuticals INC. | $32.62 | 2019 | |
| Allergan, INC. | $32.30 | 2020 | |
| Pylant Medical | $29.58 | 2025 | |
| Scilex Pharmaceuticals INC. | $26.13 | 2022 | |
| Ethicon US, LLC | $22.27 | 2019 | |
| Abbott Laboratories | $19.66 | 2019 | |
| Dynavax Technologies Corporation | $17.80 | 2025 | Heplisav-B |
| Biohaven Pharmaceutical Holding Company LTD. | $17.58 | 2022 | |
| Cranial Technologies, INC | $17.34 | 2025 | Doc Band |
| Shield Therapeutics INC | $16.33 | 2025 | |
| Cipher Pharmaceuticals US LLC | $15.80 | 2025 | Natroba, Spinosad |
| Kowa Pharmaceuticals America, INC. | $15.29 | 2019 | |
| Novartis Pharmaceuticals Corporation | $15.13 | 2019 | |
| Sanofi-Aventis U.S. LLC | $14.26 | 2020 | |
| Assertio Therapeutics, INC. | $13.04 | 2020 | |
| Genentech USA, INC. | $11.07 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Anthony Kim listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.